SAB Biotherapeutics, Inc.

Company Snapshot: SAB Biotherapeutics, Inc.

Last Change Volume High Low

Company Overview

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing immunotherapeutic human antibodies. The company applies advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce human antibodies targeted at specific diseases, including infectious diseases, such as COVID-19 and influenza; immune system disorders, including type 1 diabetes and organ transplantation; and cancer. Its DiversitAb platform is applicable to a range of human diseases. The company was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

Client News

  1. May 12 2022 SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
  2. May 12 2022 SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference
  3. Apr 5 2022 SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
  4. Mar 29 2022 SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results